skip to main content
1800 500 258

06 Jan 2015

Submission to PBS in support of eribulin

Breast Cancer Network Australia (BCNA) has made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of an application to list eribulin mesylate (Halaven) on the Pharmaceutical Benefits Scheme (PBS). Eribulin is a new chemotherapy drug for women with secondary breast cancer.

The PBAC will consider eribulin at its meeting in November.

We thank BCNA members Nicole and Sharron for sharing their personal experiences with eribulin for inclusion in our submission.

We also thank members of BCNA’s Strategic Advisory Group and the Medical Oncology Group of Australia for their assistance in reviewing the submission.

The full submission is available for download below.